Current Editions
Punching above its weight, Korea draws Western partners in CNS
A growing unpartnered CNS inventory meets rising Western appetite for BBB delivery and next-gen biologics
Deals
Product Development
AtaiBeckley’s MDMA moves anxiety scales, but key questions remain for next trial
The psychedelic’s efficacy signal in social anxiety disorder is encouraging, but durability, effect size and dosing frequency need to be clarified
Finance
With $60M round, BreezeBio turns delivery platform into internal pipeline: Venture Report
Plus: Two new NewCos emerge, Alveus draws cash for obesity pipeline, and more
BioCentury ISSN 1097-7201